Clinical Trial Update: Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) [Phase 4]

View source ↗

Summary

This Phase 4 trial update assesses patient-reported outcomes in relapsing-remitting multiple sclerosis patients who switched to fingolimod 0.5 mg.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• GILENYA (FINGOLIMOD HCL)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2014-08-08